Methylphenidate shortage — NZ supply status & alternatives

Methylphenidate

—

🇦🇺 AUST R 344272 · Teva Pharma Australia Pty Ltd

In supply · Australia

ConcertaDaytrana DeliversDaytrana , DeliversMethylphenidate Transdermal System

In supply · 🇦🇺 Australia · short in🇺🇸 US🇳🇿 NZ🇧🇪 BE

In supply in Australia

Reading today’s signals…

🇦🇺 AUAEMPA$16.17DPMQ A$36.96details →

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Methylphenidate
Brand names	Concerta, Daytrana Delivers, Daytrana , Delivers, Methylphenidate Transdermal System
Therapeutic category	Auto-created by U.S. Food and Drug Administration — Drug Shortages scraper
Controlled substance	No
Marketing-authorisation holders	Teva Pharma Australia Pty Ltd, Janssen-Cilag Pty Ltd, AFT Pharmaceuticals Pty Ltd, Generics (UK) Limited +4 more
Registrations on file	27
Patient information leaflet (PIL)	Not on file
Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 PBS · July 2026

🇦🇺 AU

● Official price on file

Ex-manufacturer

A$16.17

AEMP

Dispensed (DPMQ)

A$36.96

incl. fees

Pack

methylphenidate hydrochloride 10 mg tablet, 100

Source: PBSEffective July 2026 · AUD

Other markets

🇬🇧 GB

£3.18

Drug Tariff

🇺🇸 US

US$0.16

Acquisition

🇫🇷 FR

€55.20

Retail price

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

11 API manufacturers

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Low concentration risk

Ampac Fine Chemicals LLCChattem Chemicals INCVeranova LPSpecgx LLCCambrex Charles City INCCuria Missouri INC+5 more

Manufacturing countries: United States, India · Source: FDA List of Drug Master Files

FDA-approved products 🇺🇸 Drugs@FDA

Approved applications

Generic (ANDA)

Brand (NDA/BLA)

Mar 2024

Latest approval

Shortage status by regulator official notices

🇳🇿

New Zealand

Pharmac · 1d ago

High

🇺🇸

United States

FDA · just now

Medium

🇧🇪

FAMHP · 1mo ago

Medium

Recalls official enforcement reports

🇺🇸

DAYTRANA

Noven Pharmaceuticals Inc · Mar 2023

Class IIdetails ↗

🇺🇸

DAYTRANA

Noven Pharmaceuticals Inc · Mar 2023

Class IIdetails ↗

🇺🇸

DAYTRANA

Noven Pharmaceuticals Inc · Mar 2023

Class IIdetails ↗

🇺🇸

DAYTRANA

Noven Pharmaceuticals Inc · Mar 2023

Class IIdetails ↗

🇺🇸

DAYTRANA

Noven Pharmaceuticals Inc · Nov 2022

Class IIdetails ↗

🇺🇸

DAYTRANA

Noven Pharmaceuticals Inc · June 2022

Class IIdetails ↗

Verified timeline regulator events

🇳🇿 29 June 2026

high reported

🇳🇿 22 June 2026

high reported

🇳🇿 15 June 2026

high reported

🇳🇿 28 May 2026

high reported

🇳🇿 25 May 2026

high reported

🇺🇸 28 Feb 2025

medium reported

Sources official regulators

🇺🇸

FDA

verified just now

verify ↗

🇳🇿

Pharmac

verified 1d ago

verify ↗

🇧🇪

FAMHP

verified 1mo ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders27 registrations · 8 MA holders

Product	Strength	Form	Market	MA holder	Status
TE-METHYLPHENIDATE XR methylphenidate hydrochloride	54 mg	—	🇦🇺 AU	Teva Pharma Australia Pty Ltd	Active
TE-METHYLPHENIDATE XR methylphenidate hydrochloride	27 mg	—	🇦🇺 AU	Teva Pharma Australia Pty Ltd	Active
TE-METHYLPHENIDATE XR methylphenidate hydrochloride	36 mg	—	🇦🇺 AU	Teva Pharma Australia Pty Ltd	Active
XR ARX methylphenidate hydrochloride	36 mg	—	🇦🇺 AU	Teva Pharma Australia Pty Ltd	Active
XR ARX methylphenidate hydrochloride18 mg modified release tablet bottle	18 mg	—	🇦🇺 AU	Teva Pharma Australia Pty Ltd	Active
XR ARX methylphenidate hydrochloride	54 mg	—	🇦🇺 AU	Teva Pharma Australia Pty Ltd	Active
XR ARX methylphenidate hydrochloride	27 mg	—	🇦🇺 AU	Teva Pharma Australia Pty Ltd	Active
TEVA XR methylphenidate hydrochloride	18 mg	—	🇦🇺 AU	Teva Pharma Australia Pty Ltd	Active
TEVA XR methylphenidate hydrochloride	54 mg	—	🇦🇺 AU	Teva Pharma Australia Pty Ltd	Active
TEVA XR methylphenidate hydrochloride	36 mg	—	🇦🇺 AU	Teva Pharma Australia Pty Ltd	Active
TEVA XR methylphenidate hydrochloride	27 mg	—	🇦🇺 AU	Teva Pharma Australia Pty Ltd	Active
CONCERTA methylphenidate hydrochloride	27mg	—	🇦🇺 AU	Janssen-Cilag Pty Ltd	Active
RUBIFEN LA methylphenidate hydrochloride	30 mg	—	🇦🇺 AU	AFT Pharmaceuticals Pty Ltd	Active
RUBIFEN LA methylphenidate hydrochloride	60 mg	—	🇦🇺 AU	AFT Pharmaceuticals Pty Ltd	Active
RUBIFEN LA methylphenidate hydrochloride	40 mg	—	🇦🇺 AU	AFT Pharmaceuticals Pty Ltd	Active

+12 more registrations on file

Mederti Drug Report

Generated 3 July 2026 · Australia market · 3 regulatory sources

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.